Guggenheim Raises Johnson & Johnson (JNJ) Target on Icotyde Upside, Keeps Buy Rating [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
On April 20, Guggenheim Partners raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $266 from $244. It reiterated a Buy rating on the shares. The firm updated its model after the company's Q1 earnings and took a closer look at the Icotyde opportunity following its approval in plaque psoriasis last month. It now sees higher potential from the drug, raising its unadjusted peak revenue estimate to $14.9 billion from about $10 billion, the analyst noted. During the Q1 2026 earnings call, Vice President of Investor Relations Darren Snellgrove said worldwide sales reached $24.1 billion for the quarter. He also reported net earnings of $5.2 billion, with diluted EPS at $2.14 and adjusted diluted EPS at $2.70. Executive Vice President and CFO Joseph Wolk said the company ended the quarter with around $22 billion in cash and marketable securities, along with $55 billion in debt. He added that free cash flow came in at about $1.5 billion for the quarter. The board also appr
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026 [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026Business Wire
- BVI Medical gains CE mark for eye surgery platform [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (JNJ) – One of the 12 High Dividend Stocks Picked by Billionaire Ray Dalio [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's $7 Billion Bet Targets Cancer Treatment at the Source [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/14/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website